MURA-8518 / Mural Oncology - LARVOL DELTA

Upcoming Milestones: MURA-8518 (GlobeNewswire) - "1H 2026: Submission of Investigational New Drug or Clinical Trial Application for a phase 1 trial of MURA-8518."

IND • New P1 trial • Oncology

Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts (GlobeNewswire) - "The company expanded its pipeline in Q4 2024, by nominating two development candidates, one for its interleukin-18 (IL-18) program and one for its IL-12 program. MURA-8518 is designed to be a half-life extended, binding protein-resistant IL-18 in order to overcome the native cytokine’s limitations as a therapeutic. Mural expects to submit an Investigational New Drug (IND) Application or Clinical Trial Application (CTA) for a phase 1 trial of MURA-8518 in Q4 2025. MURA-7012 is comprised of targeted split IL-12 sub-units that preferentially self-assemble at the tumor site and are designed to limit systemic exposure."

IND • Pipeline update • Oncology

Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression (Saturday, Nov. 9: Abstract #1340) (GlobeNewswire) - "Mural Oncology...shared...poster presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)....In preclinical models, a weekly dosing regimen in mice provided durable immune responses and tumor growth inhibition. These mouse ortholog variants demonstrated resistance to IL-18BP and increased half-life, with durable expansion of immune-stimulating NK and CD8 T cells....Mural plans to nominate a development candidate for its IL-18 program by the end of 2024 and intends to submit an Investigational New Drug (IND) Application to the FDA in Q4 2025."

IND • Pipeline update • Preclinical • Oncology

Mural Oncology to Host First Virtual Investor Day on September 26, 2024 (GlobeNewswire) - "Mural Oncology plc...announced that it will host a virtual Investor Day on Thursday, September 26, 2024, beginning at 10 a.m. ET. Mural leadership, including Caroline Loew, Ph.D., CEO, and Vicki Goodman, MD, Chief Medical Officer, will provide new clinical insight into the trial design and assumptions of the company’s late-stage and potentially registrational trials of nemvaleukin, an engineered IL-2. Those trials are on track to deliver topline results in 1H 2025. Mural will also provide an overview and data presentation of its IL-18 program."

Clinical data • Clinical protocol • Preclinical • Oncology

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting (GlobeNewswire) - "Mural Oncology plc...shared poster presentations with pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at the American Association for Cancer Research (AACR) annual meeting....Abstract #4076:...Mural’s protein engineering approach is twofold: first, it introduces mutations to IL-18 that are designed to minimally impact the structure while eliminating binding to IL-18BP. Secondly, it fuses IL-18 to protein scaffolds to extend the half-life and increase the cytokine’s exposure....The optimal balance of potency and pharmacokinetic enhancement is still being determined to nominate a lead IL-18 development candidate."

Preclinical • Oncology

Mural Oncology Announces Fourth Quarter and Year End 2023 Financial Results and Provides Business Update (GlobeNewswire) - "Mural Oncology will present preclinical IL-18 and IL-12 data for the first time at the upcoming AACR conference. The company intends to nominate development candidates for these engineered IL-18 and IL-12 therapies later this year."

Pipeline update • Preclinical • Oncology